Our Core Values:

Respect

We demonstrate the value we hold for one another.

  • Act with respect towards our colleagues and others with whom we interact.
  • Communicate openly and candidly and address our differences professionally.
  • Emphasise teamwork, value each person’s contribution and collaborate in confidence and trust.
  • Look for the strengths people bring to the team.

Integrity

We do what is right.

  • Conduct our business with individual and organizational integrity.
  • Comply with the law and avoid conflicts of interest.
  • We are reliable, honest and trustworthy in our dealings.
  • Every day you are asked to follow procedures, make decisions, show leadership and develop others, do this with integrity and lead by example.

Responsibility

We hold ourselves accountable for our actions.

  • We accept personal responsibility for everything that we do and we lead by example.
  • We treat the Company’s reputation as our own.

Our Strategy:

  • The first new chemical entity in a generation to treat patients with glaucoma
  • Designed to reduce elevated intraocular pressure (IOP), the cause of vision loss in open-angle glaucoma
  • One approved product – Rhopressa® (netarsudil ophthalmic solution) 0.02% and one late development-stage product – Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
  • Both product candidates are eye drops taken once a day in the evening
  • Each product candidate has potential multiple mechanisms of action, including the novel targeting of the diseased tissue, or main drain in the eye – the source of elevated IOP; potential for disease modification
  • Significant potential in an approximately $5 billion market in the U.S., Europe and Japan, which is expected to grow to more than $8 billion by 2023All product candidates fully owned by Aerie with patents through to at least 2030

Return to Aerie jobs